India, Sept. 17 -- Calidi Biotherapeutics, Inc. (CLDI), a biotechnology company developing targeted genetic medicines, announced that it has entered into a definitive stock purchase agreement with certain accredited investors and institutional buyers for the sale of 1.03 million shares of common stock in a registered direct offering priced at $1.17 per share.
The gross proceeds from the offering are expected to be approximately $1.2 million, and Calidi intends to use the net proceeds for working capital and general corporate purposes.
The offering is expected to close on September 18, 2026.
The company's lead candidate, CLD-401, from its proprietary RedTail platform, is currently in IND-enabling studies, targeting metastatic non-small ce...